文献速递心境障碍

胼胝体下扣带回脑深部电刺激治疗难治性抑郁:多中心随机假对照试验

Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial.
PubMed 文献 · Lancet Psychiatry · 2017-10-04

本研究为前瞻性随机假对照试验,纳入难治性抑郁患者植入胼胝体下扣带回白质脑深部电刺激系统,随机接受6个月活性或假刺激后开放标签6个月。主要结局为双盲期第4-6月应答率(抑郁严重度较基线下降≥40%),活性组12例(20%)与对照组5例(17%)无统计学显著差异。研究确认了安全性和可行性,但未显示显著抗抑郁疗效。

要点

  • 胼胝体下扣带回DBS治疗难治性抑郁未显示优于假刺激的统计学显著疗效。
  • 双盲期应答率活性组20%(12例)与对照组17%(5例)差异无统计学意义。
  • 28例患者发生40起严重不良事件,其中8起(7例)与研究装置或手术相关。

核心结论

  • 胼胝体下扣带回DBS治疗难治性抑郁安全可行,但6个月双盲假对照试验未显示统计学显著抗抑郁疗效。

研究设计与样本

  • 前瞻性随机假对照试验,难治性抑郁患者植入双侧胼胝体下扣带回白质DBS系统,随机接受6个月活性或假刺激后开放标签6个月。
  • 随机化由计算机生成,各中心区组大小为3,在中心启动研究前完成。
  • 主要结局为双盲期第4-6月平均应答频率(抑郁严重度较基线下降≥40%)。
  • 在约半数拟议样本完成植入和双盲期时进行无效性分析,12个月研究结束时部分患者随访至24个月。

主要发现

  • 两组均显示改善,但双盲假对照期应答无统计学显著差异:刺激组12例(20%)vs 对照组5例(17%)。
  • 28例患者发生40起严重不良事件,其中8起(涉及7例患者)被认为与研究装置或手术相关。

关键数值与推荐

  • 主要结局应答定义为抑郁严重度较基线下降≥40%,取双盲期第4-6月平均值。
  • 双盲期应答率:活性刺激组20%(12/60)vs 假刺激组17%(5/30),差异无统计学显著性。

临床怎么用

  • 胼胝体下扣带回DBS治疗难治性抑郁安全性可行,但当前证据不支持其显著抗抑郁疗效。
  • 未来研究需探索临床特征或电极放置等因素以可能提高疗效。

局限性

  • 无效性分析后研究终止,样本量可能不足以检测小效应。
  • 部分患者随访至24个月,但长期开放标签数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Deep brain stimulation (DBS) of the subcallosal cingulate white matter has shown promise as an intervention for patients with chronic, unremitting depression. To test the safety and efficacy of DBS for treatment-resistant depression, a prospective, randomised, sham-controlled trial was conducted. METHODS: Participants with treatment-resistant depression were implanted with a DBS system targeting bilateral subcallosal cingulate white matter and randomised to 6 months of active or sham DBS, followed by 6 months of open-label subcallosal cingulate DBS. Randomisation was computer generated with a block size of three at each site before the site started the study. The primary outcome was frequency of response (defined as a 40% or greater reduction in depression severity from baseline) averaged over months 4-6 of the double-blind phase. A futility analysis was performed when approximately half of the proposed sample received DBS implantation and completed the double-blind phase. At the conclusion of the 12-month study, a subset of patients were followed up for up to 24 months. The study is registered at ClinicalTrials.gov, number NCT00617162. FINDINGS: Before the futility analysis, 90 participants were randomly assigned to active (n=60) or sham (n=30) stimulation between April 10, 2008, and Nov 21, 2012. Both groups showed improvement, but there was no statistically significant difference in response during the double-blind, sham-controlled phase (12 [20%] patients in the stimulation group vs five [17%] patients in the control group). 28 patients experienced 40 serious adverse events; eight of these (in seven patients) were deemed to be related to the study device or surgery. INTERPRETATION: This study confirmed the safety and feasibility of subcallosal cingulate DBS as a treatment for treatment-resistant depression but did not show statistically significant antidepressant efficacy in a 6-month double-blind, sham-controlled trial. Future studies are needed to investigate factors such as clinical features or electrode placement that might improve efficacy. FUNDING: Abbott (previously St Jude Medical).

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Holtzheimer PE, Husain MM, Lisanby SH, et al. Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. Lancet Psychiatry. 2017. PMID: 28988904. doi:10.1016/S2215-0366(17)30371-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。